 LA JOLLA, Calif., Sept. 01, 2021 GLOBE NEWSWIRE -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market NASDAQ:MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced an abstract entitled Improvement of Intracellular Lipid Metabolism by Tipelukast in the Pathogenesis of NASHNAFLD has been selected for poster presentation at The Liver Meeting 2021, the annual meeting of the American Association for the Study of Liver Diseases AASLD to be held November 12 - 15, 2021. MediciNovas research collaborator, Dr. Masatsune Ogura, Associate Professor at the Department of General Medical Science, Chiba University Graduate School of Medicine, will present the results of the study. Presentation details will be disseminated as they become available. 